Citius Pharmaceuticals (CTXR) News Today $1.82 +0.10 (+5.81%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.85 +0.03 (+1.65%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Citius Pharmaceuticals Announces LYMPHIR Commercialization PlansOctober 23 at 8:42 PM | msn.comCitius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesOctober 21, 2025 | prnewswire.comCitius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesOctober 21, 2025 | prnewswire.comCitius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial LaunchOctober 21, 2025 | finance.yahoo.comCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesOctober 17, 2025 | prnewswire.comCitius Oncology signs exclusive commercialization agreement with EVERSANAOctober 16, 2025 | msn.comCitius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™October 16, 2025 | prnewswire.comCitius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 10, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 9, 2025 | prnewswire.comCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchAugust 22, 2025 | prnewswire.comCitius Posts Wider Loss in Fiscal Q3August 14, 2025 | theglobeandmail.comCitius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last yearAugust 12, 2025 | msn.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides ...August 12, 2025 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | prnewswire.comCitius Oncology Announces Closing of $9.0 Million Public OfferingJuly 17, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Public OfferingJuly 16, 2025 | prnewswire.comCitius Oncology stock rises after expanding LYMPHIR distribution networkJuly 15, 2025 | investing.comCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraJuly 15, 2025 | prnewswire.comCTXR - Citius Pharmaceuticals Inc Ownership - MorningstarJuly 11, 2025 | morningstar.comMCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.deCitius Pharmaceuticals Inc (CTXR) - Investing.comJuly 8, 2025 | investing.comCitius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | prnewswire.comCitius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIRJuly 6, 2025 | msn.comCitius Pharmaceuticals Inc News (CTXR) - Investing.comJuly 1, 2025 | investing.comCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025June 17, 2025 | prnewswire.comCitius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesJune 12, 2025 | prnewswire.comCitius Pharma Announces Direct OfferingJune 11, 2025 | nasdaq.comCitius Pharmaceuticals expands authorized sharesJune 10, 2025 | investing.comCitius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesJune 10, 2025 | prnewswire.comCitius Pharmaceuticals Stock Is Soaring Monday: What's Going On?June 9, 2025 | benzinga.comMaxim Group Downgrades Citius Pharmaceuticals (CTXR)May 24, 2025 | msn.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 5, 2025 | prnewswire.comCitius Pharmaceuticals target adjusted to $4 for split at H.C. WainwrightApril 12, 2025 | markets.businessinsider.comCitius Pharmaceuticals announces $2M registered direct offering of common stockApril 2, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common StockApril 1, 2025 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology announce J-Code issued for LymphirFebruary 6, 2025 | markets.businessinsider.comCitius Pharma's LYMPHIR gains permanent J-code for billingFebruary 6, 2025 | msn.comCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesFebruary 6, 2025 | prnewswire.comCitius Pharmaceuticals announces $3M registered direct offering priced ATMJanuary 8, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanuary 8, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025January 7, 2025 | prnewswire.comCitius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesJanuary 6, 2025 | prnewswire.comD. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)December 30, 2024 | msn.comCitius Pharmaceuticals upgraded to Buy from Hold at D. Boral CapitalDecember 30, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides ...December 28, 2024 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateDecember 27, 2024 | prnewswire.comCitius Pharma Held Productive FDA Meeting To Discuss Phase 3 Mino-Lok Program, Pathway To ApprovalNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-LokNovember 25, 2024 | markets.businessinsider.com Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.550.84▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼61▲CTXR Articles Average Week Get the Latest News and Ratings for CTXR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CNTB News Today PLRX News Today IMMX News Today ORMP News Today CRDL News Today ADVM News Today BMEA News Today SCLX News Today SPRB News Today EQ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
